CaRe Prostate
Study of INKmune in Patients with metastatic castrate-resistant prostate cancer
CaRe Prostate is a Phase I/II, open label, dose escalation and expansion study of INKmune therapy in patients with metastatic castration resistant prostate cancer (mCRPC). The study is being conducted in the US.
Interested to learn more? Please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.